Avadel Pharmaceuticals PLC at Jefferies Healthcare Conference (Virtual) Transcript
Hi, good morning, everybody. This is Chris Howerton from the Jefferies biotechnology equity research team. Thank you so much for joining us for 2020 Virtual Healthcare Conference. So pleased to be joined by the next company, Avadel Pharmaceuticals.
And on behalf of the team is the -- on behalf of the Company is the management team represented by Greg Divis, the CEO; Tom McHugh, the CFO; and Jordan Dubow is there but we can't quite see him right now. So, thanks for joining me, gentlemen.
Thanks, Chris. We appreciate the opportunity to join the conference and the opportunity to talk more about Avadel and in particular FT218.
Awesome. Okay, well let's get into it then. So, maybe for those of us that aren't totally familiar with your story, what is FT218 and where are we with its development?
Yes,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |